Menlo Park-based startup Personalis, which provides medical exome and genome sequencing and interpretation services, has received $22m in Series B capital.
The round brings the company’s fundraising total to $42m, which CEO John West said gives it “a significant advantage over most new companies now entering this space.”
Abingworth led the Series B, significantly increasing its stake in the company. All of the Series A investors including Lightspeed Venture Partners and Mohr Davidow Ventures participated in the round alongside new backer Wellington Shields.
Personalis will use the funds to expand its product offering, operations and its commercial team.
Since its first customer purchase 13 months ago, the company has received $14m in customer orders for the sequencing and analysis of over 7,000 human samples.
Abingworth partner Jonathan MacQuitty said, “We saw the tremendous progress being made by Personalis on both the technical and commercial fronts, and we felt it was a great opportunity to increase our investment.
In August this year Abingworth participated in a massive $60m Series C financing round for pharmaceutical company RNA Interference.
Copyright © 2013 AltAssets